Envigo has announced that its board of directors has appointed Dr. Adrian Hardy as president and chief executive officer, effective July 1. He will join the company’s board of directors. Dr. Hardy joined Envigo in 2002 and has held various roles of increasing responsibility in sales, strategic marketing and operations, most recently serving as COO.
In related moves, Brian Cass, the previous CEO, will become executive chairman, and Andrew Baker, the previous chairman, will become chairman emeritus and remain a board member. These changes also are effective July 1.
Adrian Hardy said, “I’m delighted and extremely proud to be taking on this role at such an exciting time for Envigo and the research community. I’ve worked closely with Andrew and Brian during my time with the company and would like to thank them for their contributions to making Envigo the world class company it is today. Their vision and leadership has positioned our company as a market leader, and I look forward to continuing to work with them in their new roles as we strive to build on the growth and success of Envigo.”
Brian Cass said, “In the 18 years that I have had the privilege to lead our company I have witnessed great, and positive changes within life science research and in our company. Envigo has truly come of age and is now a crucial partner to our customers in the conduct of their research and the development of their life-changing products. I am enthusiastic that the skills, experience, and passion that Adrian brings to the role of CEO positions him to successfully lead Envigo to the next level in its development. I believe he will be a great and imaginative leader, and I look forward to continuing to work with him and the rest of the board.”
Dr. Hardy holds a BSc in human biology from King’s College London and a Ph.D. in developmental biology from University College London.